Rosemont Pharmaceuticals, a Leeds-based developer, manufacturer, and distributor of liquid medicines for over 50 years, has recently acquired Sabal Therapeutics and its affiliated companies in the USA. This strategic move will allow Rosemont to directly supply branded and generic medicines to patients with swallowing difficulties in the American market. The acquisition will further strengthen Rosemont’s presence and enable the company to provide high-quality medication directly to patients in need.
Howard Taylor, CEO of Rosemont, expressed that acquiring Sabal is a significant achievement for the company in commercializing their top-notch medicines for patients with swallowing difficulties in the US. John Denman, Vice President for the US Market at Rosemont Inc, will lead this initiative, paving the way for a successful collaboration between Rosemont and Sabal.
Jeff Bryant, President and CEO of Sabal, highlighted the collective vision of Rosemont and Sabal in improving and transforming patients’ lives through a wide range of therapeutic areas. The joint efforts of both companies aim to bring greater value to healthcare providers and their patients, marking a significant step forward in the pharmaceutical industry.
As we navigate through the challenges posed by the Covid-19 pandemic that have impacted the industry’s advertising revenues, we seek your support as readers. Your contribution, whether through a small donation or a subscription to our magazine, will assist us in sustaining quality journalism and continue delivering insightful content to our audience. By becoming a subscriber, you will gain exclusive access to our website and magazine, as well as receive special invitations to events, discounted rates for awards, and access to premium content. Join us in our mission by subscribing today and thank you for your ongoing support.
